Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Pyruvate MR Imaging in Prostate Cancer
NCT02450201Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Pyruvic acid in prostate cancer (PCa) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Peak Lactate/Pyruvate Ratio. Started Oct 2016; status: terminated.
02
Drugs
Pyruvic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02450201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450201.